| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | August 4, 2026 | 8/12 | 5 medium, 3 low flags | 3 | 0 | Call sheet → |
| Q1'26 | May 5, 2026 | 10/12 | 2 medium, 5 low flags | 7 | 0 | Call sheet → |
| Q4'25 | February 2, 2026 | 11/12 | - | 7 | 0 | Call sheet → |
| Q3'25 | November 3, 2025 | 11/12 | 1 medium, 5 low flags | 5 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Pending | FY FCF conversion guide of 85%-95% of net income Raised this quarter to 90%-100%; FY still open. |
| Q2'26 | Exceeded | Q2 organic revenue growth guide of 6.7%-8.7%, CAG recurring 8.5%-10.5% Actual Q2 organic revenue growth was approximately 9%, above the top of the range; CAG recurring came in at 10.3%, within but near the top of its range. |
| Q2'26 | Exceeded | Q2 reported revenue growth guide of 7.3%-9.3% Actual Q2 reported revenue growth was approximately 10%, above the top end of the guided range. |
| Q2'26 | Exceeded | Q2 reported operating margin guide of 33.9%-34.3% Actual Q2 reported operating margin came in at 35%, roughly 70-110bps above the top of the guided range. |
| Q2'26 | Pending | FY US clinical visit guide of approximately -1.5% Q2 actual came in better at -1.3%, yet 2H guide was held flat at -1.5% rather than raised, a conservative stance worth tracking. |
| Q2'26 | Pending | FY reported operating margin guide 32.1%-32.5% Raised to 32.3%-32.5%; FY still open. |
| Q2'26 | Pending | FY EPS guide $14.45-$14.90 Raised this quarter to $14.69-$14.94; FY still open. |
| Q2'26 | Pending | FY revenue guide $4.675B-$4.76B Revised this quarter to $4.7B-$4.745B; a range narrowing/shift, not a final-year resolution yet. |
| Q2'26 | Pending | InView DX FY placement goal of 5,500 units 2,700 placed through H1, roughly 49% of goal, management says on pace; FY not yet ended. |
| Q2'26 | Pending | F&A: 'move to a more of an unconstrained launch posture later this year' Current language still frames the process as 'controlled' with 'planned broad availability by the end of the year', same calendar window, no confirmation of unconstrained status yet. |
| Q2'26 | Pending | FNA: 'anticipate full volume ramp in the second half' Only Q2 of H2 has started and management still describes the rollout as controlled, 'broadening again meaningfully as we go into Q3' with 'full availability by the end of the year'; actual not stated as achieved on this call. |
| Q1'26 | Delivered | Technology for Life strategy with menu expansions Monthly InVue updates, new Catalyst tests, expanding platforms |
| Q1'26 | Delivered | Double-digit premium instrument installed base growth Maintained 12% growth as projected |
| Q1'26 | Delivered | Commercial expansion completion Germany, UK, Australia expansions completed and teams active |
| Q1'26 | Exceeded | Catalyst cortisol strong adoption Early adoption exceeded expectations and contributed to consumable growth |
| Q1'26 | Delivered | F&A controlled launch beginning Started controlled rollout in Q4 2025, expanding in Q2 2026 |
| Q1'26 | Delivered | Cancer DX international expansion in Q1 2026 Launched lymphoma testing in Europe and Australia as promised |
| Q1'26 | Exceeded | 5,500 InVue DX placements for 2025 Delivered nearly 6,400 units vs 5,500 target - strong execution |
| Q4'25 | Delivered | Free cash flow conversion of 95% to 100% of net income for 2025 Achieved 100% conversion-high end of range |
| Q4'25 | Delivered | Operating margin improvement of 80 to 100 basis points for full year 2025 Achieved 90 basis points improvement on comparable basis |
| Q4'25 | Delivered | CAG Diagnostics recurring revenue organic growth of 7.5% to 8.2% for full year 2025 Achieved 8% at midpoint of guidance range |
| Q4'25 | Delivered | Commercial expansion in Germany, UK, Ireland, and Australia by start of 2026 Completed and teams fully onboarded and trained |
| Q4'25 | Pending | Q1 2026 international rollout of CancerDx Reaffirmed timeline-will be key Q1 deliverable to track |
| Q4'25 | Delivered | FNA launch starting with mast cell tumor detection later in 2025 Controlled launch achieved in December as promised |
| Q4'25 | Exceeded | InVue DX instrument revenues of over $65 million for 2025 Delivered over $75 million-beat by $10M+ or ~15% |
| Q4'25 | Exceeded | InVue DX placements of approximately 6,000 during 2025 Delivered nearly 6,400 placements-beat guidance by 400+ units |
| Q3'25 | Delivered | Cancer Dx international rollout in 2026 Strengthened to Q1 2026 start with specific timing. |
| Q3'25 | Delivered | Commercial expansions in four countries in second half Modified to three international countries plus U.S. by start of 2026. |
| Q3'25 | Delivered | Catalyst Cortisol launch in late July Launched on time with strong early adoption - over 25% of customers in 3 months. |
| Q3'25 | Pending | FNA launch later in 2025 Still on track but narrowed to 'starting with mast cell tumor detection.' |
| Q3'25 | Delivered | InVue consumables revenue in line with estimates Confirmed tracking to $3,500-$5,500 per analyzer utilization targets. |
| Q3'25 | Exceeded | 5,500 InVue placements in 2025 Raised guidance to 6,000. Strong delivery on placement promises. |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.